Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Aprea Therapeutics (Nasdaq: APRE), a clinical stage biopharmaceutical company focusing on precision oncology through synthetic lethality, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York, NY.
Dr. Oren Gilad, President and CEO of Aprea, will deliver a corporate update during the conference. The presentation will be available on-demand starting at 7:00 A.M. (ET) on September 9, 2024, and will remain accessible for 90 days. Interested parties can access the webcast through the provided link.
Additionally, Aprea's management team will be available for one-on-one meetings with institutional investors during the conference. Attendees interested in scheduling a meeting are advised to contact their conference representative.
Aprea Therapeutics (Nasdaq: APRE), un'azienda biofarmaceutica in fase clinica che si concentra sull'oncologia di precisione attraverso la letalità sintetica, ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright. L'evento si terrà dal 9 all'11 settembre 2024 a New York, NY.
Il Dr. Oren Gilad, Presidente e CEO di Aprea, presenterà un aggiornamento aziendale durante la conferenza. La presentazione sarà disponibile on-demand a partire dalle 7:00 A.M. (ET) del 9 settembre 2024 e rimarrà accessibile per 90 giorni. Le parti interessate possono accedere al webcast tramite il link fornito.
Inoltre, il team di gestione di Aprea sarà disponibile per incontri individuali con investitori istituzionali durante la conferenza. I partecipanti interessati a programmare un incontro sono invitati a contattare il loro rappresentante della conferenza.
Aprea Therapeutics (Nasdaq: APRE), una compañía biofarmacéutica en etapa clínica que se centra en la oncología de precisión a través de la letalidad sintética, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversión de H.C. Wainwright. El evento está programado para del 9 al 11 de septiembre de 2024 en Nueva York, NY.
El Dr. Oren Gilad, Presidente y CEO de Aprea, presentará una actualización corporativa durante la conferencia. La presentación estará disponible bajo demanda a partir de las 7:00 A.M. (ET) del 9 de septiembre de 2024, y permanecerá accesible durante 90 días. Las partes interesadas pueden acceder al webcast a través del enlace proporcionado.
Además, el equipo de gestión de Aprea estará disponible para reuniones uno a uno con inversores institucionales durante la conferencia. Se aconseja a los asistentes interesados en programar una reunión que contacten a su representante en la conferencia.
Aprea Therapeutics (Nasdaq: APRE)는 합성 치명성을 통해 정밀 종양학에 주력하는 임상 단계의 생명공학 회사로서 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕에서 개최됩니다.
Aprea의 사장 겸 CEO인 Dr. Oren Gilad가 회의 중 기업 업데이트를 제공합니다. 프레젠테이션은 2024년 9월 9일 오전 7:00 (ET)부터 주문형으로 제공되며, 90일 동안 접근할 수 있습니다. 관심 있는 분들은 제공된 링크를 통해 웹캐스트에 접근할 수 있습니다.
또한 Aprea의 경영진 팀은 회의 기간 동안 기관 투자자와의 일대일 미팅을 위해 대기하고 있습니다. 미팅을 예약하고자 하는 참석자는 회의 대표에게 연락할 것을 권장합니다.
Aprea Therapeutics (Nasdaq: APRE), une entreprise biopharmaceutique en phase clinique axée sur l'oncologie de précision via la létalité synthétique, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024 à New York, NY.
Le Dr Oren Gilad, Président et CEO d'Aprea, présentera une mise à jour de l'entreprise lors de la conférence. La présentation sera disponible à la demande à partir de 7h00 (ET) le 9 septembre 2024 et restera accessible pendant 90 jours. Les parties intéressées peuvent accéder au webcast via le lien fourni.
De plus, l'équipe de direction d'Aprea sera disponible pour des réunions individuelles avec des investisseurs institutionnels pendant la conférence. Les participants intéressés sont invités à contacter leur représentant de conférence pour organiser une réunion.
Aprea Therapeutics (Nasdaq: APRE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf präzise Onkologie durch synthetische Letalität spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 in New York, NY, statt.
Dr. Oren Gilad, Präsident und CEO von Aprea, wird während der Konferenz ein Unternehmensupdate präsentieren. Die Präsentation wird ab dem 9. September 2024 um 7:00 Uhr (ET) auf Abruf verfügbar sein und für 90 Tage zugänglich bleiben. Interessierte können über den bereitgestellten Link auf das Webcast zugreifen.
Darüber hinaus wird das Management-Team von Aprea während der Konferenz für persönliche Gespräche mit institutionellen Investoren zur Verfügung stehen. Teilnehmer, die ein Treffen vereinbaren möchten, werden gebeten, ihren Konferenzvertreter zu kontaktieren.
- None.
- None.
DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York, NY. Details are as follows:
H.C. Wainwright 26th Annual Global Investment Conference
| Date: | September 9-11, 2024 |
| Location: | New York, NY |
| Webcast: | click here |
The above presentation is available to access “on-demand”, beginning at 7:00 A.M. (ET), on September 9, 2024. It will be available for 90 days.
Management will be available for one-on-one meetings with institutional investors. To request a meeting, please contact your conference representative.
About Aprea
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310
FAQ
When is Aprea Therapeutics presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Aprea Therapeutics at the conference?
How can investors access Aprea Therapeutics' presentation at the H.C. Wainwright conference?
Will Aprea Therapeutics management be available for meetings during the conference?
